EQRx's Aumolertinib May Be A Serious Competitive Contender For Tagrisso

 
• By Jessica Merrill

The price of aumolertinib will be "radically lower" than what has become commonplace for cancer medicines, president Melanie Nallicheri told Scrip.

Storm clouds
A new competitive threat is brewing for Tagrisso • Source: Alamy

More from ASCO

More from Conferences